|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:approves
|
gptkb:India
gptkb:UK
January 2021
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:clinical_trial
|
gptkb:India
gptkb:UK
Phase 3
|
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
gptkb:Serum_Institute_of_India
|
|
gptkbp:distribution
|
yes
|
|
gptkbp:dosage_form
|
2
yes
|
|
gptkbp:emergency_services
|
gptkb:WHO
|
|
gptkbp:first_dose_interval
|
4 to 12 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Covishield
|
|
gptkbp:is_effective_against
|
70% to 90% depending on dosage
|
|
gptkbp:is_vulnerable_to
|
gptkb:Belize
gptkb:South_Georgia_and_the_South_Sandwich_Islands
gptkb:virus
gptkb:Antigua_and_Barbuda
gptkb:Bangladesh
gptkb:British_Indian_Ocean_Territory
gptkb:Suriname
gptkb:Astra_Zeneca/_Oxford_COVID-19_vaccine
gptkb:Indonesia
gptkb:Saba
gptkb:Pitcairn_Islands
gptkb:Argentina
gptkb:Bahamas
gptkb:Brazil
gptkb:British_Virgin_Islands
gptkb:Chile
gptkb:Colombia
gptkb:Costa_Rica
gptkb:Cuba
gptkb:Curacao
gptkb:Dominican_Republic
gptkb:Ecuador
gptkb:El_Salvador
gptkb:Grenada
gptkb:India
gptkb:Jamaica
gptkb:Mexico
gptkb:Morocco
gptkb:Nepal
gptkb:Paraguay
gptkb:Peru
gptkb:Philippines
gptkb:Saint_Kitts_and_Nevis
gptkb:Sint_Maarten
gptkb:South_Africa
gptkb:Thailand
gptkb:Trinidad_and_Tobago
gptkb:UK
gptkb:Venezuela
gptkb:Zimbabwe
gptkb:Anguilla
gptkb:Aruba
gptkb:Bolivia
gptkb:Dominica
gptkb:Guatemala
gptkb:Honduras
gptkb:Montserrat
gptkb:Nicaragua
gptkb:Panama
gptkb:Saint_Lucia
gptkb:Sri_Lanka
gptkb:Turks_and_Caicos_Islands
gptkb:Falkland_Islands
gptkb:Sint_Eustatius
gptkb:Barbados
gptkb:Cayman_Islands
gptkb:Saint_Vincent_and_the_Grenadines
gptkb:Uruguay
gptkb:Bonaire
gptkb:French_Guiana
gptkb:Guyana
gptkb:Bermuda
refrigerated
varies by population
adenoviral vector vaccine
|
|
gptkbp:manufacturer
|
gptkb:Serum_Institute_of_India
|
|
gptkbp:marketed_as
|
gptkb:Covishield
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:second_dose_interval
|
4 to 12 weeks
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
nausea
fever
injection site reactions
rare thrombosis events
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:wholisting
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Astra_Zeneca
|
|
gptkbp:bfsLayer
|
4
|